Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S326.
doi: 10.21037/atm.2019.09.132.

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Kwun M Fong  1   2 , Brett G M Hughes  2   3   4 , Zarnie Lwin  2   3   4 , Ian A Yang  1   2
Affiliations
Editorial

EGFR mutations in lung cancer: not all equal in the eyes of the immune system?

Kwun M Fong et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.
    Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. Hastings K, et al. Ann Oncol. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141. Ann Oncol. 2019. PMID: 31086949 Free PMC article.

References

    1. Xu J, Jin B, Chu T, et al. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China. Lung Cancer 2016;96:87-92. 10.1016/j.lungcan.2016.01.018 - DOI - PubMed
    1. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed
    1. Hastings K, Yu H, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol 2019. [Epub ahead of print]. 10.1093/annonc/mdz141 - DOI - PMC - PubMed
    1. Network TCGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50. 10.1038/nature13385 - DOI - PMC - PubMed
    1. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378:2093-104. 10.1056/NEJMoa1801946 - DOI - PMC - PubMed

LinkOut - more resources